Research Articles

Factors contributing to anemia after uncomplicated falciparum malaria

The factors contributing to anemia in falciparum malaria were characterized in 4,007 prospectively studied patients on the western border of Thailand. Of these, 727 patients (18%) presented with anemia (haematocrit < 30%), and 1% (55 of 5,253) required blood transfusion. The following were found to be independent risk factors for anemia at admission: age < 5 years, a palpable spleen, a palpable liver, recrudescent infections, being female, a prolonged history of illness (> 2 days) before admission, and pure Plasmodium falciparum infections rather than mixed P. falciparum and Plasmodium vivax infections. The mean maximum fractional fall in hematocrit after antimalarial treatment was 14.1% of the baseline value (95% confidence interval [CI], 13.6-14.6). This reduction was significantly greater in young children (aged < 5 years) and in patients with a prolonged illness, high parasitemia, or delayed parasite clearance. Loss of parasitized erythrocytes accounted for < 10% of overall red blood cell loss. Hematological recovery was usually complete within 6 weeks, but it was slower in patients who were anemic at admission (adjusted hazards ratio [AHR], 1.9, 95% CI, 1.5-2.3), and those whose infections recrudesced (AHR, 1.2, 95% CI, 1.01-1.5). Half the patients with treatment failure were anemic at 6 weeks compared with 19% of successfully treated patients (relative risk, 2.8, 95% CI, 2.0-3.8). Patients coinfected with P. vivax (16% of the total) were 1.8 (95% CI, 1.2-2.6) times less likely to become anemic and recovered 1.3 (95% CI, 1.0-1.5) times faster than those with P. falciparum only. Anemia is related to drug resistance and treatment failure in uncomplicated malaria. Children aged < 5 years of age were more likely than older children or adults to become anemic. Coinfection with P. vivax attenuates the anemia of falciparum malaria, presumably by modifying the severity of the infection.

This article has been cited by other articles:

				C. Hatz, J. Soto, H. D. Nothdurft, T. Zoller, T. Weitzel, L. Loutan, F. Bricaire, F. Gay, G.-D. Burchard, K. Andriano, et al. Treatment of Acute Uncomplicated Falciparum Malaria with Artemether-Lumefantrine in Nonimmune Populations: A Safety, Efficacy, and Pharmacokinetic Study Am J Trop Med Hyg, February 1, 2008; 78(2): 241 - 247. [Abstract] [Full Text] [PDF]

				R. N. Price, E. Tjitra, C. A. Guerra, S. Yeung, N. J. White, and N. M. Anstey Vivax Malaria: Neglected and Not Benign Am J Trop Med Hyg, December 1, 2007; 77(6_Suppl): 79 - 87. [Abstract] [Full Text] [PDF]

				A. W. Pawluczkowycz, M. A. Lindorfer, J. N. Waitumbi, and R. P. Taylor Hematin Promotes Complement Alternative Pathway-Mediated Deposition of C3 Activation Fragments on Human Erythrocytes: Potential Implications for the Pathogenesis of Anemia in Malaria J. Immunol., October 15, 2007; 179(8): 5543 - 5552. [Abstract] [Full Text] [PDF]

				A. A. Lamikanra, D. Brown, A. Potocnik, C. Casals-Pascual, J. Langhorne, and D. J. Roberts Malarial anemia: of mice and men Blood, July 1, 2007; 110(1): 18 - 28. [Abstract] [Full Text] [PDF]

				P. G. MCQUEEN and F. E. MCKENZIE Competition for red blood cells can enhance Plasmodium vivax parasitemia in mixed-species malaria infections. Am J Trop Med Hyg, July 1, 2006; 75(1): 112 - 125. [Abstract] [Full Text] [PDF]

				K. J. Evans, D. S. Hansen, N. van Rooijen, L. A. Buckingham, and L. Schofield Severe malarial anemia of low parasite burden in rodent models results from accelerated clearance of uninfected erythrocytes Blood, February 1, 2006; 107(3): 1192 - 1199. [Abstract] [Full Text] [PDF]

				F. ZAMORA, O. RAMIREZ, J. VERGARA, M. AREVALO-HERRERA, and S. HERRERA HEMOGLOBIN LEVELS RELATED TO DAYS OF ILLNESS, RACE, AND PLASMODIUM SPECIES IN COLOMBIAN PATIENTS WITH UNCOMPLICATED MALARIA Am J Trop Med Hyg, November 1, 2005; 73(5_suppl): 50 - 54. [Abstract] [Full Text] [PDF]

				T. Voza, A. M. Vigario, E. Belnoue, A. C. Gruner, J.-C. Deschemin, M. Kayibanda, F. Delmas, C. J. Janse, B. Franke-Fayard, A. P. Waters, et al. Species-Specific Inhibition of Cerebral Malaria in Mice Coinfected with Plasmodium spp. Infect. Immun., August 1, 2005; 73(8): 4777 - 4786. [Abstract] [Full Text] [PDF]

				M. L. Craig, J. N. Waitumbi, and R. P. Taylor Processing of C3b-Opsonized Immune Complexes Bound to Non-Complement Receptor 1 (CR1) Sites on Red Cells: Phagocytosis, Transfer, and Associations with CR1 J. Immunol., March 1, 2005; 174(5): 3059 - 3066. [Abstract] [Full Text] [PDF]

				K. Stepniewska, W. R.J. Taylor, M. Mayxay, R. Price, F. Smithuis, J.-P. Guthmann, K. Barnes, H. Y. Myint, M. Adjuik, P. Olliaro, et al. In Vivo Assessment of Drug Efficacy against Plasmodium falciparum Malaria: Duration of Follow-Up Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4271 - 4280. [Abstract] [Full Text] [PDF]

				L. M. ERHART, K. YINGYUEN, N. CHUANAK, N. BUATHONG, A. LAOBOONCHAI, R. S. MILLER, S. R. MESHNICK, R. A. GASSER JR., and C. WONGSRICHANALAI HEMATOLOGIC AND CLINICAL INDICES OF MALARIA IN A SEMI-IMMUNE POPULATION OF WESTERN THAILAND Am J Trop Med Hyg, January 1, 2004; 70(1): 8 - 14. [Abstract] [Full Text] [PDF]

				E. Tjitra, J. Baker, S. Suprianto, Q. Cheng, and N. M. Anstey Therapeutic Efficacies of Artesunate-Sulfadoxine-Pyrimethamine and Chloroquine-Sulfadoxine-Pyrimethamine in Vivax Malaria Pilot Studies: Relationship to Plasmodium vivax dhfr Mutations Antimicrob. Agents Chemother., December 1, 2002; 46(12): 3947 - 3953. [Abstract] [Full Text] [PDF]